A Phase III, Randomized, Two Armed, Parallel, Double-blind, Active-controlled, Equivalency Clinical Trial to Determine the Therapeutic Efficacy and Safety Between Cetuximab® (Produced by CinnaGen) and FOLFIRI Compared With Erbitux® (Cetuximab, the Reference Drug, Produced by Merck Company) and FOLFIRI for RAS Wild-type Metastatic Colorectal Cancer Patients
Phase of Trial: Phase III
Latest Information Update: 19 Jun 2018
At a glance
- Drugs Cetuximab (Primary) ; Fluorouracil; Folinic acid; Irinotecan
- Indications Adenocarcinoma; Colorectal cancer
- Focus Therapeutic Use
- Sponsors CinnaGen
- 31 Aug 2018 Biomarkers information updated
- 13 Feb 2018 Planned End Date changed from 22 Nov 2018 to 1 Feb 2020.
- 13 Feb 2018 Planned primary completion date changed from 22 Feb 2018 to 30 Nov 2019.